Information Provided By: 
Fly News Breaks for October 11, 2018
TTPH
Oct 11, 2018 | 18:55 EDT
Piper Jaffray analyst Edward Tenthoff lowered his price target on Tetraphase to $6 to reflect the company's launch of XERAVA in the treatment of complicated intra-abdominal infections in the U.S. at $175 per day, which is below his previously projected $200 price point. The analyst keeps his Overweight rating however, adding that he hopes that the "responsible pricing" will drive the drug's "uptake in the larger empiric or first-line market as a broad-spectrum antibiotic".
News For TTPH From the Last 2 Days
There are no results for your query TTPH
